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Abstract 
 
Cytarabine (ara-C) is the key agent for treating acute myeloid leukemia. After being transported 
into leukemic cells, ara-C is phosphorylated, by several enzymes including deoxycytidine kinase 
(dCK), to ara-C triphosphate (ara-CTP), an active metabolite, and then incorporated into DNA, 
thereby inhibiting DNA synthesis. Therefore, the cytotoxicity of ara-C depends on the production 
of ara-CTP and the induction of apoptosis. Here, we established a new ara-C-resistant acute 
myeloid leukemia cell line (HL-60/ara-C60) with dual resistance characteristics of the 
anti-antimetabolic character of decreased ara-CTP production and an increase in the 
antiapoptotic factors Bcl-2 and Bcl-XL. We further attempted to overcome resistance by 
augmenting ara-CTP production and stimulating apoptosis. A relatively new nucleoside analog, 
9-β-D-arabinofuranosylguanine (ara-G), and the small molecule apoptosis inhibitor YC137 were 
used for this purpose. The established subclone HL-60/ara-C60 was 60-fold more 
ara-C-resistant than the parental HL-60 cells. HL-60/ara-C60 cells exhibited low capacity for  
dCK protein expression, which resulted in decreased ara-CTP production. HL-60/ara-C60 cells 
were also refractory to ara-C-induced apoptosis due to overexpression of the antiapoptotic 
proteins Bcl-2 and Bcl-XL. Combination treatment of ara-C with ara-G augmented the dCK 
protein level, thereby increasing ara-CTP production and subsequent cytotoxicity. Moreover, the 
combination of ara-C with the Bcl-2 antagonist YC137 produced greater apoptosis than ara-C 
alone. Though the combination of ara-C with two drugs could only partially overcome ara-C 
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resistance in ara-C-resistant cells, the three-drug combination of ara-C, ara-G and YC137 
substantially overcame resistance. These findings suggest possible combination strategies for 
overcoming ara-C resistance by augmenting ara-CTP production and reversing refractoriness 
against the induction of apoptosis in ara-C resistant leukemic cells.  
 
 Introduction 
 
Cytarabine (1-β-D-arabinofuranosylcytosine; ara-C), a pyrimidine nucleoside analog, is key in the 
treatment of acute myeloid leukemia (AML).(1-3) Standard induction therapy, which consists of 
conventional doses of ara-C for 7 days plus anthracycline for 3 days, provides remission rates of 
over 70% for AML.(1-5) Nevertheless, only 40% of patients are long-term survivors and most 
relapse with the development of drug resistance. Thus, overcoming ara-C resistance is essential 
to improve clinical outcomes.(1-6) 
Ara-C is transported into leukemic cells by membrane transporters including the human 
equilibrative nucleoside transporter 1 (hENT1).(7) Inside the cell, ara-C is phosphorylated to 
ara-C 5′-monophoshate by the rate-limiting enzyme deoxycytidine kinase (dCK) and 
subsequently to ara-C 5′-triphosphate (ara-CTP), an active metabolite of ara-C. Ara-CTP is then 
incorporated into DNA strands in the S phase of the cell cycle, resulting in the inhibition of DNA 
synthesis and the consequent induction of apoptosis.(1,8-11)   
We have extensively investigated the mechanisms of resistance to ara-C to improve 
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therapeutic efficacy.(12-18) Because the toxicity of ara-C depends on its cellular activation to 
ara-CTP and the induction of apoptosis, cellular factors that can regulate ara-C activation and 
the apoptotic pathway may be critical in ara-C resistance. Thus, we hypothesized that strategies 
that could enhance ara-CTP production and stimulate apoptosis would augment ara-C’s 
cytotoxicity and overcome resistance to it in leukemic cells. 
Here, we report that we have established a unique new ara-C-resistant AML cell line with 
coexpression of anti-antimetabolic and antiapoptotic factors. We further attempted to overcome 
ara-C resistance by augmenting ara-CTP production and stimulating apoptosis. A relatively new 
nucleoside analog, 9-β-D-arabinofuranosylguanine (ara-G, the metabolite of nelarabine), and the 
small molecule apoptosis inhibitor YC137 were used for this purpose. Ara-G is a purine 
nucleoside analog that is similar to ara-C but that has a slightly different activation pathway. (19-22) 
YC137 disrupts the function of the antiapoptotic molecule Bcl-2, inducing cytochrome c release 
from mitochondria and activating caspase-9. YC137 has been shown to induce apoptosis of 
hematopoietic progenitor cells overexpressing Bcl-2.(23,24) 
 
 
Materials and Methods 
Chemicals and Reagents. 
  Ara-C was purchased from Sigma-Aldrich (St. Louis, MO, USA). Ara-G was purchased from RI 
Chemical. Inc (Orange, CA, USA). YC137 was purchased from Calbiochem (Darmstadt, 
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Germany). All other chemicals were of analytical grade. 
 
 Development of an ara-C-resistant leukemic cell line.  
Human leukemia HL-60 cells were cultured in RPMI1640 media supplemented with 10% 
heat-inactivated fetal bovine serum at 37˚C in humidified air containing 5% carbon dioxide. To 
develop an ara-C-resistant HL-60 variant, parental HL-60 cells were cultured in media containing 
ara-C. The cultures were observed daily and allowed to grow. Drug concentrations were 
gradually increased on subsequent passages, and an ara-C-resistant subclone (HL-60/ara-C60) 
isolated using the limiting-dilution method.  
 
Growth inhibition assay. 
HL-60 cells and HL-60/ara-C60 cells (1×105/ml) were incubated for 72 h with different 
concentrations of anticancer agents. The growth-inhibitory effects were evaluated using either 
the trypan blue dye exclusion assay or the sodium 
3′-(1-[(phenylamino)-carbonyl-3,4-tetrazolium])-bis(4-methoxy-6-nitro)benzene sulfonic acid 
hydrate (XTT) assay, according to the manufacturer’s instructions (Roche Diagnostics, 
Indianapolis, IN, USA) with slight modifications.(18)  
 
Determination of intracellular production of ara-CTP. 
The acid-soluble fraction (nucleotide pool) was extracted from HL-60 cells or HL-60/ara-C60 
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cells (1×106/ml, 10 ml), treated or untreated. HPLC was then used to determine intracellular 
ara-CTP as described in previous studies.(12,15) 
 
Nucleoside transport capacity.  
To evaluate the capacity of membrane nucleoside transporters, ara-C uptake was quantified 
using the method of Wiley et al with slight modifications.(7,16) Non-facilitated drug uptake was 
determined in the presence of 3 μM nitrobenzylthioinosine (Sigma), which interferes with the 
function of membrane nucleoside transporters. The capacity of the transporter was determined 
as the difference between drug uptake in the absence and presence of nitrobenzylthioinosine. 
 
Determination of dCK protein expression using Western blotting. 
Protein expression of dCK was determined using Western blot analysis as described 
previously.(18) Mouse monoclonal anti-dCK, which was developed in the Department of 
Pediatrics, Mie University School of Medicine(25) and rabbit polyclonal anti-Bad, rabbit polyclonal 
anti-Bcl-2, rabbit polyclonal anti-Bcl-XL antibodies (Cell Signaling Technology, Beverly, MA, 
USA) and anti-actin antibody (Sigma-Aldrich) were used as the primary antibodies. Anti-mouse 
IgG antibody and anti-rabbit IgG-horseradish peroxidase-conjugated antibody (Amersham 
Biosciences, UK) were used as the secondary antibody. The band density was measured using 
an imaging densitometer. 
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Determination of apoptotic cell death using nuclear staining with Hoechst 33342 and flow 
cytometry.  
Treated or untreated cells (1×105/ml) were incubated with 20 μg/ml Hoechst 33342 at room 
temperature for 15 min. The samples were observed by fluorescence microscopy, and cells with 
apoptotic morphology were determined by counting 100 cells per treatment and were also 
analyed using an Annexin-V-FLUOS Staining Kit (Roche Diagnostics, Indianapolis, IN, USA). 
Flow cytometory was analyed with the use of FACSCanto II (BD Bioscience, NJ, USA). 
 
Statistical analyses.  
All statistical analyses were performed using Microsoft Excel 2007 software (Microsoft, 
Redmond, WA, USA). All graphs, curves and columns were generated using GraphPad Prism 
software (version 5.0) (GraphPad Software, Inc. San Diego, CA, USA). Values of P ≤ 0.05 were 
considered statistically significant. 
 
Results 
 
Establishment of ara-C-resistant leukemic cells.  
The XTT assay demonstrated that HL-60/ara-C60 cells were about 60-fold more resistant to 
ara-C than HL-60 cells (Table 1). HL-60/ara-C60 cells exhibited cross resistance to the similar 
nucleoside analogs gemcitabine (dFdC) and cladribine (2CdA) (Table 1). Thus, the 
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ara-C-resistant subclone (HL-60/ara-C60) was successfully established. 
Intracellular ara-CTP production and ara-C-related factors.  
Intracellular ara-CTP is a surrogate marker of ara-C-induced cytotoxicity, so the production of 
ara-CTP was evaluated in both cell lines. When cells were incubated for 6 h with different 
concentrations of ara-C, the production of ara-CTP increased in a concentration-dependent 
manner (Fig. 1A). However, the ara-CTP level was significantly lower in HL-60/ara-C60 cells 
than HL-60 cells, suggesting that ara-CTP is critical to the sensitivity of cells to ara-C.  
For successful production of ara-CTP, ara-C must be transported into cells and 
phosphorylated to the ara-C nucleotide. When cells were pulsed with ara-C, the drug was rapidly 
incorporated in both cell lines (Fig. 1B). However, the analog uptake was invisibly lower in 
HL-60/ara-C60 cells than HL-60 cells. Moreover, HL-60/ara-C60 cells exhibited lower expression 
of the rate-limiting enzyme dCK than HL-60 cells (Fig. 1C). Therefore, these results suggest that 
the development of ara-C resistance in HL-60/ara-C60 cells was in part attributable to altered 
ara-C-related factors that resulted in the cells’ low capability for ara-CTP production. 
 
Sensitization of the ara-C-resistant variant by ara-G.  
One strategy that increases the intracellular ara-CTP concentration is pre-treatment with a 
purine nucleoside analog such as fludarabine 
(9-β-D-arabinofuranosyl-2-fluoroadenine-5′-monophosphate, F-ara-AMP). (26,27) Theoretically, the 
intracellular active metabolite F-ara-A triphosphate inhibits ribonucleotide reductase, thereby 
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reducing the dCTP pool. This stimulates dCK activity, which then enhances the production of 
ara-CTP. Here, a relatively new purine nucleoside analog, ara-G, and conventional F-ara-A  
were similarly evaluated. Combination of a minimally toxic concentration (10 μM) of either ara-G 
or F-ara-A with 10 μM ara-C similarly enhanced ara-CTP production in both cell lines compared 
with treatment with ara-C alone (Fig. 2A and B). The combination effect was more potent for 
ara-G than F-ara-A in HL-60/ara-C60 cells (Fig. 2B). This increase in ara-CTP production is in 
accordance with the augmentation of dCK protein expression by the addition of ara-G to ara-C 
(Fig. 1C). Moreover, we demonstrated small-scale production of ara-GTP in both HL-60 and 
HL-60/ara-C60 cells on treatment with ara-G (Fig. 2C). The combination also enhanced ara-C’s 
cytotoxicity in both cell lines (Fig. 2D). Thus, these results suggest that ara-G augments dCK 
expression, thereby increasing ara-CTP production and as a result enhancing ara-C cytotoxicity .  
 
 Expression of Bcl-2-family proteins in leukemic cells.  
Many anticancer agents exert their cytotoxicity by inducing apoptotic cell death.(28,29) The Bcl-2 
family of proteins contains key regulators of the mitochondrial pathway of apoptosis. Of these, 
Bcl-2 has been found to be overexpressed in many cancer cells, including B-cell-derived 
lymphomas. Western blot analysis demonstrated increased protein levels of antiapoptotic Bcl-2 
and Bcl-XL in HL-60/ara-C60 cells compared with HL-60 cells (Fig. 3). Thus, inhibition of 
apoptotic function was suggested to be involved in the mechanisms of resistance to ara-C in 
HL-60/ara-C60 cells. 
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Sensitization of ara-C-resistant cells by Bcl-2 inhibitor.  
Antiapoptotic Bcl-2 might represent a target for the treatment of cancers, typically those in 
which Bcl-2 is overexpressed. The Bcl-2 inhibitor YC137 was designed to inhibit the binding of 
the proapoptotic Bid BH3 peptide to Bcl-2, thus disrupting an interaction essential for 
antiapoptotic activity.(24) When ara-C-resistant HL-60/ara-C60 cells were treated with ara-C plus 
YC137, the induction of apoptosis was more prominent than in cells treated with ara-C alone (Fig. 
4B and E). The combination also induced apoptosis in ara-C-sensitive HL-60 cells, and the 
enhancement was apparent (Fig. 4A and D). The addition of YC137 augmented the 
growth-inhibition effects of nucleoside analogs including ara-C, dFdC and 2CdA on 
HL-60/ara-C60 cells (Fig. 4C, Table 2). These results suggest inhibition of Bcl-2 as a possible 
strategy to overcome the resistance of leukemia cells to ara-C.  
 
Sensitization of ara-C-resistant cells by the combination of ara-G and Bcl-2 inhibitor.  
We examined the effect of the combination of ara-C with ara-G and Bcl-2 inhibitor, respectively, 
in HL-60/ara-C60 cells. However, the effect on ara-C resistance was poor. Therefore, we 
examined the effect of the combination of ara-G, YC137 and ara-C in HL-60/ara-C60 cells and 
found it to almost fully overcome ara-C resistance. In order to examine whether this 
phenomenon is specific to the HL-60/ara-C60 cell line, we observed the combination effect of the 
three drugs in HL-60/AD cell lines that we had previously established(13) and showed 34-fold 
resistance to ara-C and also expressed Bcl-2. Thus, ara-C resistance can be almost fully 
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overcome even in the HL-60/AD cell line (Table 3). 
 
Discussion 
Ara-C is one of the most effective chemotherapeutic agents used in the treatment of AML. 
However, the resistance of leukemic cells to ara-C remains a major drawback. We and others 
have extensively investigated the mechanisms of ara-C resistance in vitro and in vivo.(12-18) 
Deficient dCK activity, decreased nucleoside transporter content, decreased DNA polymerase 
sensitivity, overexpression of the cytidine deaminase gene, and enhanced cN-II activity have 
been reported to be associated with ara-C resistance in vitro.(30-32) Clinically, low hENT1 
transcript level, increased cN-II expression, decreased dCK expression, and increased 
cN-II/dCK expression ratio were associated with poor therapeutic outcomes of ara-C-based 
chemotherapy.(33-35)  Moreover, resistance to ara-C might develop due to the antiapoptotic 
nature of cancer cells including the X-linked inhibitor of apoptosis protein (XIAP) and Bcl-2.(36,37) 
Thus, the development of cellular resistance to ara-C is mainly a result of decreased capability to 
produce intracellular ara-CTP and inhibition of apoptosis. 
Here, we have demonstrated a reduced capability to yield ara-CTP (Fig. 1) and 
resistance to the induction of apoptosis (Fig. 3) in a newly established ara-C-resistant leukemic 
cell line (HL-60/ara-C60). In this resistant cell line, reduced ara-CTP production was attributable 
to a reduction in dCK protein (Fig. 1C) while its antiapoptotic nature was due to overexpression 
of Bcl-2 and Bcl-XL (Fig. 3). The addition of the purine nucleoside analog ara-G to ara-C 
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augmented the dCK protein level (Fig. 1C), thereby increasing ara-CTP production (Fig. 2A and 
B) and cytotoxicity (Fig. 2D). The combination of the Bcl-2 antagonist YC137 with ara-C provided 
a greater amount of apoptosis than ara-C alone (Fig. 4). The contribution of Bcl-2 
overexpression was also noted in the exertion of cytotoxic effects of dFdC and 2CdA (Fig. 4C).  
Ara-G is a guanosine nucleoside analog that exerts specific cytotoxicity in 
T-lymphoblasts compared with myeloblasts and B-lymphoblasts.(20,21) No cytotoxic effect was 
shown in HL-60 and HL-60/ara-C60 cell lines (Table 1). Ara-GTP was produced in these cells 
(Fig. 2C), although at a much lower level than in T-cells. This is reported to be a result of reduced 
ara-GTP half-life in these cells when compared with T-cells.(38-40) Like ara-C, ara-G must be 
phosphorylated intracellularly to ara-G triphosphate for its cytotoxic effect as well as the 
augmentation of ara-CTP production. However, the activation pathway of ara-G is not identical to 
that of ara-C.(19-22) Ara-G is transported into the cell via both nitrobenzylthioinosine-sensitive and 
-insensitive equilibrative nucleoside transporters including hENT1 and concentrative nucleoside 
transporter 3.(19) Inside the cell, ara-G is phosphorylated to its monophosphate form by not only 
dCK but also the mitochondrial enzyme deoxyguanosine kinase. Therefore, ara-GTP has been 
suggested to be an active enhancer of ara-C cytotoxicity even in ara-C-resistant leukemic cells 
that  decreased dCK activity (Fig. 2C). We have demonstrated that the addition of ara-G to 
ara-C increased dCK expression, ara-CTP production and subsequent cytotoxicity in 
HL-60/ara-C60 cells (Table 1, Fig. 1 and 2). On the contrary, F-ara-A, which utilizes the 
activation pathway in common with ara-C, was less effective for enhancing ara-CTP production 
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in HL-60/ara-C60 cells (Fig. 2B). Thus, these results suggest that ara-G has potential; to 
overcome cellular resistance to ara-C.  
Apoptosis is important for normal development, host defense, and suppression of 
oncogenesis, and faulty regulation of apoptosis has been implicated in cancer. The Bcl-2 family 
of proteins contains key regulators of the mitochondrial pathway of apoptosis and includes both 
antiapoptotic molecules such as Bcl-2 and Bcl-XL, and proapoptotic molecules such as Bax, Bak, 
Bid, and Bad.(23) Many types of cancer overexpress antiapoptotic Bcl-2 family members.(24) Here, 
Bcl-2 protein was overexpressed in HL-60/ara-C60 cells (Fig. 3), suggesting that the altered 
apoptotic function would contribute to the development of resistance to ara-C. Addition of the 
Bcl-2 inhibitor YC137 to ara-C induced more apoptosis in HL-60/ara-C60 cells than ara-C alone 
(Fig. 4). Apoptosis was also enhanced when YC137 was combined with other nucleoside 
analogs (dFdC, 2CdA), to which HL-60/ara-C60 cells showed cross resistance (Fig. 4). These 
results suggest that the antiapoptotic nature mediated by Bcl-2 overexpression plays a critical 
role in ara-C resistance in leukemic cells. 
Moreover, synergistic effects were observed on the combination of ara-G with ara-C and YC137 
with ara-C in both HL-60/ara-C60 and HL-60/AD cells, though both only partially overcame ara-C 
resistance (Table 3). Therefore, we examined the effect of ara-G, YC137 and ara-C in both 
ara-C-resistant cell lines. The three-drug combination almost full overcame ara-C resistance in 
both ara-C-resistant cell lines (Table 3). These results suggest that addition of two drugs of 
different nature could dramatically augment ara-C cytotoxicity in ara-C-resistant cells. 
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In conclusion, the development of drug resistance in cancer cells is usually multifactorial. 
Our findings suggest that reduced ara-CTP production and refractoriness of the induction of 
apoptosis may be major mechanisms of resistance to ara-C in leukemic cells. We may need to 
examine the involvement of both ara-C activation and antiapoptosis, and provide tailor-made 
treatment to reverse ara-C resistance. Moreover, optimum combination strategies should be 
developed based on our understanding of the mechanisms of resistance in ara-C-based 
chemotherapy for leukemia. 
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Figure legends 
Figure. 1. 
(A) Production of intracellular ara-CTP. Cells (1 x 106 cells/ml, 10 ml) were incubated for 4 h with 
1, 2, 5, 10 μM ara-C. The acid-soluble fraction was extracted from each sample and applied to 
HPLC. O, HL60, ●; HL60/ara-C60. Each value represents the mean±SD of at least three 
independent experiments. *P ≤ 0.05 (B) Transport of ara-C into parental and ara-C-resistant cells. 
Membrane nucleoside transport of ara-C was assessed by pulsing the cells with 0.32 μM tritiated 
ara-C for 0, 20, 40, and 60 s, followed by quantification of cellular drug uptake by scintillation 
counting. Open bars, HL-60 cells; closed bars, HL-60/ara-C60 cells. Each value represents the 
mean±SD of at least three independent experiments. (C) dCK protein expression. The cells (1 x 
106 cells/ml, 10 ml) were incubated with 10 μM ara-G for 2 h (or not), followed by washing in 
media and incubation with 10 μM ara-C for 3 h. dCK protein expression was determined using 
Western blot analysis.  
 
Figure. 2. 
(A, B) Enhancement of ara-CTP production by ara-G. Cells (1 x 106 cells/ml, 10 ml) were 
incubated with 10 μM F-ara-A or ara-G for 2 h (or not), followed by washing in media and 
incubation with 10 μM ara-C for 3 h. (C) Cells (1 x 106 cells/ml, 10 ml) were incubated with 10 μM 
ara-G for 4h. The intracellular ara-GTP was measured using HPLC as described in Materials and 
Methods (A, B, C). (D) Growth inhibition was determined using the trypan blue dye exclusion 
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assay after the cells had been treated with ara-C plus ara-G as described above. Open bars, 
without ara-G; closed bars, with ara-G. Each value represents the mean±SE of at least three 
independent experiments. *P ≤ 0.05. 
 
Figure. 3. 
Protein expression levels of Bad, Bcl-XL, Bcl-2 in HL-60 cells and HL-60/ara-C60 cells; Western 
blot analysis. 
 
Figure. 4. 
(A, B, D, E) Enhancement of apoptotic cell death by the combination of ara-C and the Bcl-2 
inhibitor YC137. Cells were treated with 0.005 μM ara-C (A,D), 0.05 μM ara-C (B,E) or 2.5 μM 
YC137, or both in combination for 72 h. Induction of apoptosis was determined using nuclear 
staining with Hoechst 33342 (A,B) and was analyzed by flow cytometry (D,E). (C) Cells were 
incubated with a given nucleoside analog with or without co-incubation with 2.5 μM YC137 for 72 
h. The IC50 was determined using the XTT assay. Ara-C, cytarabine; dFdC, gemcitabine, 2CdA, 
cladribine. Open bars, HL-60 cells; closed bars, HL-60/ara-C60 cells. Each value represents the 
mean±SE of at least three independent experiments. *P ≤ 0.05. 
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Table 1.   Sensitivity of HL-60 cells and HL-60/ara-C60 cells to anticancer agents 
IC50 (μM) 
HL-60              HL-60/ara-C60          RR 
Ara-C                   0.08±0.003            4.91±0.23            61 
dFdC                  0.004±0.0002           0.12±0.03            30 
2CdA                   0.07±0.006            17.1±2.82           244 
Ara-G                     >1000                  >1000              - 
Ara-C + Ara-G             0.1±0.08             0.23±0.05           2.3 
CPT-11                0.008±0.0002           0.04±0.004            5 
Cells were treated with each agent for 72 h, followed by the determination of IC50 using the XTT 
assay. RR, relative resistance calculated as the ratio of the IC50 of HL-60/ara-C60 cells relative to 
that of HL-60 cells. Ara-C, cytarabine; dFdC, gemcitabine; 2CdA, cladribine; CPT-11, irinotecan; 
ara-G, 9-β-D-arabinofuranosylguanine; ND, not determined due to insensitivity to ara-G. Values 
for IC50 are the means±S.D. 
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Table 2.  YC137 augmented growth inhibition effects of nucleoside analogs on HL-60/ara-C60 
cells  
Drugs        IC50 (µM)  
YC137        5.8±0.34 
Ara-C             4.91±0.23 
Ara-C + YC137       0.3±0.23  
dFdC             0.12±0.03 
dFdC + YC137            0.05±0.02 
2CdA             17.1±2.82 
2CdA + YC137       3.9±1.8 
Cells were incubated with a given nucleoside analog with or without co-incubation with 2.5μM 
YC137 for 72 h. The IC50 was determined using the XTT assay. Ara-C, cytarabine; dFdC, 
gemcitabine; 2CdA, cladribine. Values for IC50 are the means±S.D. 
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Table 3.  Ara-G and YC137 augmented growth inhibition effects of ara-C on ara-C-resistant 
cells 
                          IC50 (μM) 
      HL-60       HL-60/ara-C60 (RR)       HL-60/AD (RR) 
Ara-C      0.08±0.003  4.91±0.23 (61)    2.7±0.59 (34) 
Ara-C + Ara-G      0.1 ±0.08         0.23±0.05 (2.3)    0.4±0.14 (4) 
Ara-C + YC137     0.04±0.003   0.3±0.23 (7.5)   0.17±0.19 (4.3) 
Ara-C + Ara-G + YC137   0.05±0.001   0.1±0.06 (2)    0.07±0.01 (1.4) 
Cells were incubated with a given nucleoside analog with or without co-incubation with 10μM 
ara-G or 2.5μM YC137 for 72 h. The IC50 was determined using the XTT assay. RR, relative 
resistance calculated as the ratio of the IC50 of HL-60/ara-C60 and HL-60/AD cells relative to that 
of HL-60 cells. Ara-C, cytarabine; Ara-G, 9-β-D-arabinofuranosylguanine. Values for IC50 are the 
means±S.D. 
 
 
 
